Triple Negative Breast Cancer News and Research

RSS

Researchers reveal how molecular imaging can solve breast cancer mysteries

In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer.

7 Feb 2012

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.

11 Dec 2011

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.

9 Dec 2011

Initial results from whole-genome sequencing trial for triple negative breast cancer

Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

First results from whole-genome sequencing clinical trial on triple negative breast cancer

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin-(trastuzumab).

2 Dec 2011

Life Beyond Cancer's 12th annual retreat from November 18 to 20

Austin, Texas: Some 150 cancer survivors, health care providers and patient advocates will discover ways to inspire, empower and motivate those to a Life Beyond Cancer, November 18 to 20 at the Lakeway Resort and Spa.

17 Nov 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

The Translational Genomics Research Institute (TGen) is part of a team of medical investigators receiving a $3.5 million grant from Susan G. Komen for the Cure to study triple-negative breast cancer, a highly aggressive form of this cancer that disproportionately affects African-Americans.

26 Sep 2011

Genetic testing for breast and ovarian cancer

Experts from Cancer Treatment Centers of America (CTCA) provide some clues as to who should be using these tests. They explain that women who have been diagnosed with cancer and/or people who have a strong family history of cancer can consider genetic testing. Red flags to consider are anyone in the family who developed cancer at a young age, multiple family members who developed cancer, if a person experienced bilateral cancer (cancer in both breasts), breast and ovarian cancer in the same woman, or cancer appeared where it wasn’t expected (like breast cancer in men)

26 Sep 2011

Conference to discuss novel studies that address how inherited genes cause breast cancer

A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer. Research into understanding and treating hereditary breast cancer will be presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

4 Aug 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Researchers discover overactive genes that drive triple-negative breast cancer cells

Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.

2 Jun 2011

Breast cancer cells utilize tissue stem cell EMT for tumor metastasis

Researchers at the University of North Carolina at Chapel Hill School of Medicine, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer.

7 May 2011

Researchers identify unexpected triple-negative breast cancer marker

German researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy.

5 May 2011

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Triple Negative Breast Cancer News and Research

Researchers reveal how molecular imaging can solve breast cancer mysteries

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Initial results from whole-genome sequencing trial for triple negative breast cancer

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

First results from whole-genome sequencing clinical trial on triple negative breast cancer

Life Beyond Cancer's 12th annual retreat from November 18 to 20

Blueberry powder may control triple negative breast cancer

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

Genetic testing for breast and ovarian cancer

Conference to discuss novel studies that address how inherited genes cause breast cancer

Verastem raises $32 million to develop targeted cancer stem cell therapies

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Researchers discover overactive genes that drive triple-negative breast cancer cells

Breast cancer cells utilize tissue stem cell EMT for tumor metastasis

Researchers identify unexpected triple-negative breast cancer marker

IMPAKT 2011 conference to highlight new breast cancer studies

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News